Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

Clinically HER2+ (cHER2+) breast cancer (BC) can no longer be considered a single BC disease entity in terms of trastuzumab responsiveness. Here we propose a framework for predicting the response of cHER2+ to trastuzumab that integrates the molecular distinctions of intrinsic BC subtypes with recent...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Martin-Castillo, Begoña, Lopez-Bonet, Eugeni, Cuyàs, Elisabet, Viñas, Gemma, Pernas, Sonia, Dorca, Joan, Menendez, Javier A.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Research Perspective
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741696/
https://ncbi.nlm.nih.gov/pubmed/26474458
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires